---
document_datetime: 2024-10-01 13:30:52
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/esmya-epar-all-authorised-presentations_en.pdf
document_name: esmya-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9900068
conversion_datetime: 2025-12-18 08:49:20.677184
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

| MA (EU) Number   | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging                  | Pack size   |
|------------------|-------------------|------------|-----------------------|---------------------------|--------------------------------------|-------------|
| EU/1/12/750/001  | Esmya             | 5 mg       | Tablet                | Oral use longer           | blister (Alu/PVC/PE/PVDC) authorised | 28 tablets  |
| EU/1/12/750/002  | Esmya             | 5 mg       | Tablet                | Oral use                  | blister (Alu/PVC/PE/PVDC)            | 84 tablets  |
| EU/1/12/750/003  | Esmya             | 5 mg       | Tablet                | Oral use                  | blister (Alu/PVC/PE/PVDC)            | 30 tablets  |
| EU/1/12/750/004  | Esmya             | 5 mg       | Tablet                | Oral use                  | blister (Alu/PVC/PVDC)               | 28 tablets  |
| EU/1/12/750/005  | Esmya             | 5 mg       | Tablet                | Oral use                  | blister (Alu/PVC/PVDC)               | 84 tablets  |